VIR News - Candlesense

Vir Biotechnology to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the...

Conference

about 23 hours ago

Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2025 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the second quarter ended June 30, 2025. “We achieved seve...

Are there any regulatory or reimbursement risks associated with the highlighted programs that could affect long‑term valuation? How might the new data influence analyst coverage, target price revisions, or recommendation upgrades/downgrades? What is the anticipated impact of the update on the stock's short‑term price momentum and trading volume?

Earnings

20 days ago

Vir Biotechnology Successfully Initiates all Trials in ECLIPSE Registrational Program for Chronic Hepatitis Delta

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All three trials in the Company’s registrational ECLIPSE ...

How could potential regulatory setbacks or trial delays impact the stock’s upside/downside potential? Will the outcomes of ECLIP2 and ECLIP3 provide sufficient data to support a robust FDA or EMA filing strategy? What are the key enrollment milestones and risk factors that could trigger volatility in VIR stock?

Clinical trials

20 days ago